Spectrum Pharmaceuticals stock (ticker: SPPI) represents ownership in a biotechnology company developing treatments for cancer and monoclonal antibody drug resistance. The company focuses on late-stage oncology therapies, with its primary products including POZENI® (poziotinib) for non-small cell lung cancer and EVOMENESTRO™ (elacestrant) for estrogen receptor-positive breast cancer.
Spectrum generates revenue through drug sales, licensing agreements, and milestone payments from partnerships. Its lead product, POZENI, targets specific mutations in lung cancer, while EVOMENESTRO addresses hormone-resistant breast cancer. The company also earns income from collaborations with larger pharmaceutical firms, such as its partnership with Menarini Group for POZENI's global development and commercialization.
Spectrum's pipeline includes several promising candidates:
These drugs position Spectrum in competitive oncology markets, where targeted therapies command premium pricing.
As of mid-2024, SPPI trades on the Nasdaq with a market capitalization of approximately $300 million. The stock has seen volatility typical of small-cap biotech equities, with significant moves following clinical trial results. For example, positive Phase 3 data for EVOMENESTRO in 2023 sent shares up 40% in a single day. However, Spectrum remains unprofitable, with quarterly losses averaging $20 million due to high R&D expenses.
Investors often confuse SPPI with spectrum brand stock, a Canadian consumer goods company. Unlike Spectrum Pharmaceuticals, Spectrum Brand focuses on household products like Arm & Hammer and Black Flag., some assume Spectrum Pharmaceuticals is a large-cap player, but it remains a mid-tier biotech firm with limited commercial-stage assets.
Another mistake is assuming all of Spectrum's drugs target the same cancer type. While POZENI and EVOMENESTRO both treat oncological conditions, they address different mutations and patient populations, reducing direct competition between them.
To analyze Spectrum Pharmaceuticals stock, review its SEC filings, particularly the latest 10-Q and 10-K reports. Pay attention to:
Spectrum's stock price reacts sharply to trial readouts and FDA decisions. For instance, a 2022 Phase 2 failure for POZENI in colorectal cancer caused a 25% drop. Investors should prepare for such volatility when trading SPPI.